- Home
- CPTNW
CPTNW
Cepton Inc. Warrant
as 12-18-2024 4:00pm EST
Cepton Inc provides lidar-based solutions for a range of markets such as automotive, smart cities, smart spaces and smart industrial applications. The company's patented MMT-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
| Founded: | N/A | Country: | United States |
| Employees: | 87 | City: | SAN JOSE |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cepton Inc. Warrant News
CPTNW Breaking Stock News: Dive into CPTNW Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Cepton, Inc. Reports Third Quarter 2024 Results
Simply Wall St.
3 months ago
Cepton (NASDAQ:CPTN) Is In A Good Position To Deliver On Growth Plans
Business Wire
4 months ago
Cepton, Inc. Reports Second Quarter 2024 Results
Business Wire
5 months ago
Cepton Signs Definitive Agreement to be Acquired by Koito
Business Wire
6 months ago
Net Asset Value(s)
PR Newswire
6 months ago
Dstny honored with 'Employee Wellbeing Award'
PR Newswire
6 months ago
Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024
GlobeNewswire
6 months ago
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
Compare CPTNW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPTNW Cepton Inc. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.